Key statistics dashboard for Grace Therapeutics, Inc. (GRCE). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
Stock Data
| Price | $2.14 |
| Market Cap | $35M |
| Beta | 0.69 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.70 |
| Price / Book | 0.77 |
| P/S | 0.00 |
| P/FCF | -3.38 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 11.47 |
| Quick Ratio | 11.47 |
| Cash Ratio | 11.00 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 11.56 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.79 |
| Cash per share | 0.80 |
| FCF per share | -0.60 |
| Tangible Book Value per share | 0.72 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Related companies: ABVC · ATNM · CALC · LTRN · LVTX · OKUR · PDSB
Explore sector: Healthcare · Biotechnology
More sections of GRCE: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks